While etanercept appears to have to impose the lowest infection risk among TNF inhibitors, but as outlined by Gerriets et al., each drug has varying effectiveness against each condition, making it harder to reduce infections in individuals with conditions that are unable to be treated with lower infection risk agents (Wallis et al., 2004; Biancheri et al., 2015; Gerriets et al., 2021). The gene discussed is TNF; the disease is infection.